biology-technology-1/queens-secures--26-23163-3b25m-for-uks-cyber-safety-9301-1/www.qub.ac.uk

Breaking Biology Technology:Sirius Genomics Announces Change in Leadership 2 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3 Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4 AEterna Zentaris Announces Appointment of New Board Member 2 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3 Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4

[0] Sirius Genomics Announces Change in Leadership [0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea [0] AEterna Zentaris Announces Appointment of New Board Member [0] Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics

Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2 Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3 Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4 Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5 Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6 Daniel K. Spiegelman Elected to Board of Directors of Omeros 2 Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2 Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17 2009 6162 1 Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17 2009 6162 2 Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 1 Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 2 Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 3 Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 4 Shire Re Launches FOCUS an Online Personalized Patient Support Program for Adults with ADHD Taking Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 6160 5 Natural Alternatives International Inc Announces Filing of Patent Infringement Lawsuit 6158 1 Natural Alternatives International Inc Announces Filing of Patent Infringement Lawsuit 6158 2

[0] Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium [0] Daniel K. Spiegelman Elected to Board of Directors of Omeros [0] Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research